Key terms
About ORMP
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ORMP news
Mar 19
9:02am ET
Scilex announces repayment of balance of convertible debentures
Mar 18
5:33pm ET
Oramed Pharmaceuticals Welcomes New Audit Committee Chair
Mar 18
5:23pm ET
Oramed Pharmaceuticals Updates Stock Sale Strategies and Partners
Feb 20
8:52am ET
Oramed Pharmaceuticals CEO Updates Shareholders on Strategy
Feb 15
11:05am ET
Biotech Alert: Searches spiking for these stocks today
Feb 02
11:07am ET
Biotech Alert: Searches spiking for these stocks today
Jan 02
6:20am ET
Analysts Conflicted on These Healthcare Names: Oramed Pharm (ORMP), Accolade (ACCD) and Milestone Pharmaceuticals (MIST)
No recent press releases are available for ORMP
ORMP Financials
Key terms
Ad Feedback
ORMP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ORMP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range